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Abstract
Aims: Within the guidelines of the research programme
on medical prescription of narcotics for opioid addicts
(PROVE), heroin, morphine, and methadone were pre-
scribed to heavily opioid addicted individuals in Switzer-
land since 1994. This contribution analyses the course of
dose levels during the treatment period. Design: Natural-
istic description of consumed dosages per day and
month. Setting and Participants: The study describes the
dosages prescribed to all individuals who began outpa-
tient treatment in the PROVE programme in Switzerland
between 1994 and 1996. Measurements: Consumed
amount of narcotics per day and the course of dosage of
injectable heroin in different treatment regimes. Find-
ings: Heroin was the most frequently prescribed narcot-
ic. Of all consumption days, heroin had been applied in
77% as injection and in 9% in a smokeable form. The
mean daily dosage was 474 mg for intravenous applica-
tion and 993 mg for the smokeable form. Second most
frequent was the prescription of oral methadone, in most
cases in combination with heroin. The mean amount of
daily consumption of oral methadone was 53 mg. There
were dosage differences between treatment regimes.
During the course of treatment the mean dosage for
injectable heroin per day decreased significantly and,
depending on the treatment regime, almost linearly.
Conclusions: The significance of heroin dosages in he-
roin-assisted therapy for treatment outcome should be
further explored, especially in the light of the markedly
higher dosages in Switzerland compared to the UK. Dur-
ing the treatment period, dosages did not increase but
generally decreased, indicating no further increase in tol-
erance.
Copyright © 2004 S. Karger AG, Basel
Introduction
Background and Swiss Drug Policy
In the 1980s and 1990s Switzerland experienced an
increase in opiate users and, as a consequence, a marked
increase in health and social problems. The onset of AIDS
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and the formation of an open drug scene raised public
awareness of drug problems and public pressure was
brought on policy makers to take appropriate action [1].
The Swiss government launched a comprehensive pro-
gramme, the aims of which were as follows: to reduce the
number of new drug consumers; to increase the number of
addicts who become abstinent; to reduce opiate-associat-
ed health consequences and the social discrimination and
stigmatisation of consumers and/or addicts, and to pro-
tect society against drug-related harm and fight against
drug-related organised crime [2]. Different measures were
implemented to reach these goals. The present strategy
integrates prevention, abstinence treatment, harm reduc-
tion and repression in equal proportions [2, 3].
Treatment Options for Heroin Addicts
A wide variety of therapeutic protocols were estab-
lished to treat opiate-dependent patients. In the early
1990s there were about 1,300 residential treatment places
available for abstinence therapy for patients who had
been detoxified earlier. Additionally, roughly 10,000 pa-
tients received methadone within the framework of main-
tenance therapies [2].
Even though Switzerland had a wide variety of drug
treatment programmes, it became clear that there was no
suitable therapeutic option for a group of severely ad-
dicted individuals and poly-drug users. Specifically, these
were drug addicts in their thirties who had tried, to no
avail, a variety of outpatient and inpatient treatments,
including oral methadone programmes. To the general
public the drug users were a particular burden because of
their criminal activities to generate income, including
prostitution. From a public health perspective this group
of drug users was particularly important because they
were at high risk of HIV infection or overdose. For these
reasons the government decided in 1991 to launch a
research programme to investigate whether these margin-
alised drug addicts could be integrated into another treat-
ment programme that would lead to improved health con-
ditions, social rehabilitation, and finally to abstinence
[2].
This research programme on medical prescription of
narcotics for opioid addicts (PROVE) began in 1994.
Approval of the study was obtained from the Swiss Acade-
my of Medical Sciences’ supra-regional ethics committee.
The intervention consisted of opioid maintenance treat-
ment together with psychosocial and medical support.
Heroin, morphine, and methadone were given as substi-
tution agents. The medical prescription of narcotics for
the opioid addicts programme was evaluated by social,
medical, pharmacological, economical and criminological
studies and showed positive results [4, 5]. Based on the
positive experiences in Switzerland, a randomised con-
trolled clinical trial has been conducted in the Nether-
lands (www.ccbh.nl) and various initiatives are under way
in a few Western countries [6–8].
Dosages
Several studies [9–15] have pointed to the positive cor-
relation between dosage and treatment success in metha-
done maintenance programmes. As an example, partici-
pants with a sufficiently high methadone dosage showed
lower dropout rates and reduction in illegal side consump-
tion when compared to participants with low methadone
dosages. Publications on dosing in heroin maintenance
programmes can be found far less often than publications
on methadone substitution. Nevertheless, there are some
studies by British researchers where heroin dosages had
been described. It should be noted, however, that some of
these studies have been conducted at an earlier stage of
the heroin epidemic in Europe.
For instance, Gardner and Connell [16] reported on
107 opioid addicts who had been patients at a drug depen-
dence clinic between March 1968 and February 1969.
Based on addiction severity at treatment onset, patients
were divided into 5 groups according to the doses con-
sumed before therapy, with dosages ranging from 60 to
610 mg. Two patients with very high doses of 1,200 mg
and 1,500 mg were included. During treatment patients
were given either the same or, to a large degree, a lower
dose than the one they were accustomed to. No mean dose
was reported. In addition to heroin, oral methadone was
prescribed, usually in doses between 10 and 20 mg.
In another study, Mitcheson [17] examined both he-
roin and methadone dosages in specialised treatment clin-
ics between 1977 and 1984. Even though the number of
patients increased during that time from 982 to 1,081, the
number of patients given heroin-assisted treatment de-
creased from 239 to 82, as did the mean dosage of heroin.
If heroin was the only substance given, the daily dose
decreased from 250 mg in 1977 to 181 mg in 1984. When
prescribed in combination with methadone, the daily dos-
age was 158 mg in 1977 and 130 mg in 1984.
In a controlled randomised study the acceptance of
heroin for intravenous application was compared with
oral methadone and the effects of these different treat-
ment models were analysed [18]. Patients admitted to the
programme were those who wished to continue substitu-
tion treatment with heroin but had been denied participa-
tion in other treatment programmes. Patients with psy-
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chotic diseases were excluded. Of the 96 heroin addicts
who started the treatment programme, 52 were assigned
to participate in a treatment programme with oral metha-
done and 44 were assigned to participate in a treatment
programme with intravenous heroin. After 12 months,
29% of the patients in the methadone treatment pro-
gramme and 74% of those in the heroin treatment pro-
gramme were still participating in the trial. Daily dosages
used in this programme were 10–120 mg oral methadone
and 30–120 mg intravenous heroin.
Another British study examined the scope and practice
of opioid prescriptions by physicians in the year 1995
[19]. For this purpose, data from a quarter of the 10,616
public pharmacies in England and Wales had been col-
lected; 3,846 of the analysed opioid prescriptions related
to 3,562 methadone prescriptions and 64 related to heroin
prescriptions. The daily intravenous heroin dosages were
10–500 mg, with a mean dose of 175 mg.
In their cohort study, McCusker and Davies [20] com-
pared the outcome in the heroin prescription cohort with
that in methadone-prescribed patients. They found that
after 6 months, the heroin-prescribed group manifested
lower levels of psychopathology and showed a higher
retention rate. The use of illicit drugs was comparable
across most substances. Significantly more heroin-pre-
scribed participants reported using illicit cocaine. Be-
sides, both groups reported greater use of illicit heroin
than at the time of the first interview. The mean dosage of
opiates prescribed to the heroin prescription cohort was
253 mg pharmaceutical heroin in injectable and smoke-
able form (unfortunately, the authors did not differentiate
between the two forms) at the first interview. The mean
dose in the control group was 72 mg of oral methadone.
Six months later, the mean prescribed dose increased to
295 mg in the heroin group and decreased to 60 mg in the
methadone group. The authors explained the increase in
illegal heroin use as a result of higher tolerance. The high-
er doses given in the course of treatment seemed to sup-
port this argument.
The most recent survey concerning heroin dosages also
took place in England and was published in 1998 [21].
The study described the feasibility of treatment pro-
grammes for opioid addicts with injectable heroin and
methadone. In this trial the daily dosages of both heroin
and methadone were limited to 200 mg. Thirty-seven of
the 58 participants (64%) chose intravenous heroin as
medication, 21 (36%) chose intravenous methadone.
Within the first 3 months of treatment, the average pre-
scription for 37 patients was 181 mg of intravenous
heroin per day; the 12-month average was 185 mg per
day. Fifteen participants treated with intravenous heroin
reported withdrawal symptoms during the night (41% of
37). They received additional oral methadone (on average
24 mg per day).
In sum, there is little knowledge with respect to heroin
dosage in substitution treatment programmes for long-
term opioid addicts with severe social and medical prob-
lems. The purpose of this current analysis is to provide
data on heroin dosages prescribed in the Swiss PROVE
programme. Some results from experimental sub-studies
on dosage within PROVE have already been published
[22–25]. This contribution analyses the course of dosage
of all patients in a certain time period in the main study.
Participants and Methods
Samples
The present study evaluated daily records of all 1,151 patients
who entered an outpatient treatment programme between 1 January
1994 and 30 June 1996 and who received heroin, methadone or mor-
phine as part of their treatment. The research took place from 1 Janu-
ary 1994 to 31 December 1996. The shortest time someone partici-
pated in the PROVE programme was 1, the longest was 1,087 days;
mean duration was 433 (SD = 281) days. Thirty percent of the sample
were women and 70% were men. Mean age at entry was 30.8 (SD =
5.8) years. On average, patients had consumed heroin on a regular
basis for 10.4 (SD = 5.2) years.
The evaluation of the course of dosage used data from the sub-
sample of participants who stayed at least 18 months on the pro-
gramme and who had not interrupted their treatment with intrave-
nous heroin for more than 15 days per month due to imprisonment,
hospitalisation, holidays or unauthorised absence. To be on the pro-
gramme for 18 months or more, the patient had to have started the
heroin-supported treatment programme before July 1995. Table 1
shows the characteristics of the overall cohort and the sample used
for the 18-month evaluation. As a result of the large sample size and
the overlapping membership of the same individuals in both groups,
no statistical tests for significant differences were made.
Narcotics
During the research period (1994–1996), the physicians on duty
could prescribe intravenous and smokeable heroin as well as intrave-
nous and oral morphine and methadone. Originally, the design called
for experimental studies comparing heroin-assisted treatment with
other treatment regimes [4]. However, due to the low acceptance of
alternative treatment options and the frequent, severe side effects of
morphine [4, 22] (which had been one of the main comparison
regimes planned), the study was changed into a naturalistic cohort
design with a predominant prescription of heroin [4]. As a result of
this change, after May 1995 there was a maximum of 800 treatment
places available for heroin prescription of a total of 1,000 treatment
places for all substances. All injectable narcotics had to be consumed
under supervision at the treatment centre. All data of methadone
dosages refer to the use of the racemate (a mixture of the D- and
L-forms), which is common in Switzerland.
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Table 1. Comparison of the entry
characteristics of the overall cohort
(n = 1,151) and the sub-sample, for which
the course of dosage has been evaluated
(n = 139)
Parameter Overall Sub-sample
(18 months)
Socio-demographic characteristics
Sex 1,151 139
Male
Female
800 (70%)
351 (30%)
89 (64%)
50 (36%)
Age, years, mean B SD 31B5.8 31B5.3
Social integration
Living situation 1,133 [18] 139
With parents
As a lodger
In a rented flat/house
In an institution
Homeless
125 (11%)
216 (19%)
499 (44%)
148 (13%)
146 (13%)
16 (11%)
24 (17%)
67 (48%)
23 (7%)
9 (17%)
Employment status 1,116 [35] 138 [1]
Full or part-time
Temporary, pension, household
Without work
182 (16%)
462 (42%)
473 (42%)
17 (12%)
55 (40%)
66 (48%)
Addiction-specific characteristics
Addicts 1,130 [20] 139
Duration of addiction
mean B SD, years 10.5B5.5 10.3B5.3
Daily consumers in the last 4 weeks prior to admission of1
Alcohol 198 (18%)/1,112 [39] 29 (21%)/136 [3]
Benzodiazepine 276 (24%)/1,129 [22] 27 (20%)/134 [5]
Cannabis 333 (30%)/1,094 [57] 49 (36%)/135 [4]
Cocaine 335 (30%)/1,100 [51] 48 (35%)/136 [3]
Therapy-specific characteristics
Heroin use 1,032 139
Heroin dose, mg, mean B SD 474B206 504B203
Figures in square brackets denote missing values.
1 Self-reported data.
Dosing Practices in Different Treatment Centres
Initially, treatment centres were free to choose their own dosage
regime, but by 1996 guidelines and recommendations had been
worked out. In 18 treatment centres three different main dosage
regimes were initially established, with small differences between the
treatment regimes, as outlined below.
Partly based on experiences with computerised dispensing of
methadone, two centres, both opening at least three times a day,
decided to work with a computerised dispensing modus for heroin.
After the initial dosing and following a discussion between the treat-
ing physician and the patient, the patient could choose dosage and
application form within a maximal daily dose (calculated on the basis
of past dosages to the same patient) and an individualised, maximum
single dose based on his/her opioid tolerance (regime 1). This system
has been developed to allow the user to choose a dosage while provid-
ing a safety framework. The reasoning and detailed operationalisa-
tion has been described in detail elsewhere [26]. Overall, this regime
resulted in the highest initial doses.
One treatment centre dispensed narcotics only twice a day (re-
gime 2). In this regime, only the treating physician could determine
dosages. There were no upper limits.
The remaining 15 treatment centres used dosage regime 3, which
limited the maximum daily dose for injectable heroin to 800 mg. As
in treatment regime 2, dosages were fixed and could only be changed
by the responsible physician. Even though there was a maximum dai-
ly dosage in this regime, there were exceptions. All the 15 treatment
centres were open at least 3 times a day.
Materials
For scientific purposes and security reasons as well as for narco-
tics control, each dose of opioid dispensed in the treatment centres
was recorded in a data-processing system developed specifically for
that purpose [26].
The evaluation of the treatment data was conducted at the Addic-
tion Research Institute, Zurich (SPSS 6.1.1. for Macintosh and SYS-
TAT 8.0). Repeated analyses of variance were used to estimate
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Table 2. Overview of the prescribed
substances of 1,151 participants
498,073 consumption days
Substance Consumption
days, %1
Dispenses
per day2
Mean daily
dose, mg3
SD, mg
Heroin i.v. (mono or comb.) 77 2.6 474 206
Heroin i.v. (mono) 49 2.8 492 205
Heroin smoked (mono or comb.) 9 2.2 993 755
Heroin smoked (mono) 2 3.8 1,856 483
Morphine i.v. (mono or comb.) 2 2.5 372 215
Morphine i.v. (mono) 1 2.8 391 232
Morphine p.o. (mono or comb.) 4 1.4 324 254
Morphine p.o. (mono) 1 2.0 574 256
Methadone i.v. (mono or comb.) 3 1.0 111 44
Methadone i.v. (mono) 3 1.0 109 43
Methadone p.o. (mono or comb.) 30 1.0 53 44
Methadone p.o. (mono) 5 1.0 98 39
Mono = Only 1 substance in 1 application form was consumed on a given day; comb. =
combined consumption.
1 Due to multiple count, the sum adds up to more than 100%.
2 Mean per consumption day, not identical with the number of cigarettes or pills.
3 Mean daily dosage of the reported substance or application form.
Table 3. Amount of heroin consumption with respect to the different dosage regimes
Regime 1
88,610 consumption days
consumption
days, %
mean daily
dosage, mg (SD)
Regime 2
92,252 consumption days
consumption
days, %
mean daily
dosage, mg (SD)
Regime 3
317,211 consumption days
consumption
days, %
mean daily
dosage, mg (SD)
Heroin i.v. (mono or comb.) 50 573 (277) 73 487 (190) 86 455 (191)
Heroin i.v. (mono only) 20 673 (302) 28 507 (207) 62 473 (184)
Consumption days = Days with heroin consumption/all possible days (all days in treatment); mean daily dosage =
arithmetic mean of heroin consumption on consumption days.
changes over time. The within-subject factor were the different time
points of each individual. In addition, dosage regime (all three
described) was introduced as a between-subject factor.
Results
Daily Dosages
PROVE participants consumed narcotics on 92% of
498,073 patient days. The remaining 8% they were either
in hospital, in prison or otherwise absent from the treat-
ment centre. According to the treatment plan the most
frequently consumed narcotic was heroin. It was injected
on 77% of all consumption days and smoked on 9%. The
mean daily dosage on days that the participant received
heroin was 474 mg for intravenous and 993 mg for the
smokeable application. The second most frequently con-
sumed narcotic was oral methadone (30%), however, in
most cases it was taken in combination with heroin.
Table 2 shows the mean amounts of daily consump-
tion. It also shows that heroin and morphine were injected
on average 3 times a day, whereas methadone was con-
sumed only once a day (in agreement with the pharmaco-
kinetic characteristics of the substances).
Table 3 shows differences of heroin prescriptions ac-
cording to the dosage regimes.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 2
:3
7:
27
 P
M
46 Eur Addict Res 2004;10:41–48 Gschwend/Rehm/Blättler/Steffen/
Seidenberg/Christen/Bürki/Gutzwiller
Fig. 1. Heroin dosages in the three treat-
ment regimes. Least square estimates of he-
roin doses over time (regime 1: n = 22;
regime 2: n = 33; regime 3: n = 84; total n =
139).
Table 4. Most frequent combinations (1,151 participants, 498,073
consumption days)
Combinations Consumption days, %
Double combinations
Heroin i.v., methadone p.o. 22
Heroin i.v., heroin smoked 4
Heroin i.v., morphine p.o. 2
Heroin smoked, morphine p.o. 1
Morphine i.v., methadone p.o. 1
Heroin smoked, methadon p.o. 1
Triple combinations
Heroin i.v., heroin smoked, methadone p.o. 1
Substance and Application Combinations
Of interest was the finding on the number of combina-
tions of narcotics or application forms that participants
received. With around 22% of all treatment days, the
combination of intravenous heroin and oral methadone
was frequent. On around 4% of all consumption days,
heroin was injected as well as smoked. In these cases, no
further narcotics were used on site. Other combinations
were rarely used. Table 4 shows the most frequent combi-
nations used in PROVE.
Heroin Dosages during the Course of Treatment
Figure 1 shows the mean amount of injected heroin
over the course of treatment (after the initial three
months), separated by treatment regime. The first three
months were excluded as they reflect the initial adjust-
ment period where changes in dosage were quite fre-
quent.
An inspection of the graph indicates three main effects.
(1) An almost linear decline in heroin doses over time;
(2) a main effect for treatment regime, with regime 1 dis-
pensing higher mean doses than regime 2, and regime 2
dispensing higher doses than regime 3, and (3) an interac-
tion effect, indicating different developments of dosing
over time. The group under regime 1 showed the steepest
decline over time, regime 2 showed no decline at all, but
dosage remained stable, and regime 3 showed a decline,
but not as steep as regime 1.
Repeated analyses of variance of the individual data
(n = 139) revealed all these effects to be significant. The
main effect for declining doses explains about 12% of the
total variance within subjects (F14, 1904 = 19.9; p ! 0.001).
The mean decrease per month during the 15 months ana-
lysed was 5.9 mg of heroin.
Analyses including the intake of methadone showed
that lower heroin dosages were not compensated with
higher methadone dosages. An analysis of all opioids in
methadone equivalents [25] revealed a highly significant
decrease in consumption on all measures used (F14, 1932 =
19.4; p ! 0.001; with Greenhouse-Geisser correction:
F3, 451 = 19.4; p ! 0.001; explained variance: 12.3%). In
sum, the mean dose of heroin declined after initial adjust-
ment of dosage without compensation with methadone.
There was also a main effect of treatment regime, i.e.
the three treatment regimes differed (F12, 136 = 7.78; p !
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0.001). This effect explains about 11% of the variance
between subjects.
Finally, there was a highly significant interaction be-
tween treatment regime and time. Regime 1 started out
with the highest mean doses but also declined at the stee-
pest rate. In the last months, regime 1 used lower heroin
doses than regime 2. Regime 2 had an almost constant
dosage level. Regime 3 started out lowest, but still de-
clined, although at a lower rate than regime 1. Overall, the
interaction effect accounted for about 6% of the within
variance (F28, 1904 = 4.9; p ! 0.001).
Discussion
In agreement with the treatment plan, intravenous
heroin was the most frequently consumed narcotic. It was
consumed exclusively on about one half of all treatment
days. All other substances played only a minor role. With
respect to mono consumption, the mean amount of inject-
able heroin used was 492 mg per day. In combination
with other opioids, the mean daily amount of heroin con-
sumption was reduced to 474 mg. According to the dosage
regimes in the included treatment centres, differences
could be noticed with respect to the level of dosage. In the
long run, dosages seemed to converge although there were
still differences at the end of the 15-month period of anal-
ysis. It is not clear whether the differences in decline
between regime 1 and regime 3 are entirely due to the dif-
ference in initial dosages or whether there are other deter-
mining factors. However, it can be clearly stated that
overall dosages declined, even when patients could choose
their daily maintenance dosage themselves (regime 1).
The decline may be interpreted in terms of motivation
of the patients to reduce their opioid dose in the long run.
This would be in line with findings that the longer the
participants stay on heroin-assisted treatment, the higher
the chances they will enter abstinence treatment [5].
Another potential explanation for the dose reductions
may be the fact that patients on tight maintenance doses
of heroin do not experience the maximum flash and thus
decrease dosage [25]. Whatever the reason, there was no
continuous rise in heroin dosages in the long term, one of
the potential threats of this type of treatment, as discussed
above. Additionally, illegal drug use also decreased during
participation in PROVE [4].
The daily dosages dispensed during PROVE were
clearly higher than those that could be found in other
studies. Five British studies used heroin dosages 2–4
times lower compared to the study presented here [17–
21]. However, the samples may also be different with
respect to length of opiate dependence, and different lev-
els of somatic and psychiatric comorbidity make direct
comparisons difficult. Thus questions of adequate heroin
dosage for the treatment of drug addicts cannot be fully
answered by the data presented here or by other currently
available data. As the choice of the ‘right’ dosage is a cen-
tral question in every substitution treatment programme,
our contribution can only be seen as a basis for further
studies that should try to solve the question of dosage
and dosage regime using randomised controlled clinical
trials.
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